InMed Pharmaceuticals Inc (NASDAQ: INM) shares are trading higher Tuesday after the company said it selected a lead Alzheimer's drug candidate following positive proof-of-concept study data

What Happened: InMed's INM-901 demonstrated unique pharmacological effects in Alzheimer's disease in preclinical studies. The company now plans to advance the Alzheimer's candidate ...

Full story available on Benzinga.com